Journal article
PS1157 EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL
P Ghia, I Flinn, N Lamanna, M Montillo, Á Illés, G Etienne, J Delgado, B Kuss, C Tam, F Offner, F Bosch, M Davids, U Jäger, F Cymbalista, D Weaver, S Lustgarten, H Youssoufian, S Stilgenbauer
HemaSphere | Wiley | Published : 2019
Abstract
Background:Duvelisib (DUV), a first‐in‐class oral dual PI3K‐δ,γ inhibitor, is approved for treatment of relapsed/refractory (R/R) CLL/SLL after ≥ 2 prior therapies. In the phase 3 DUO trial, DUV 25 mg BID significantly improved efficacy vs ofatumumab (OFA; mPFS, 13.3 vs 9.9 mo; HR, 0.52 [P < .0001]; ORR, 74% vs 45% [P < .0001]) in pts with R/R CLL/SLL (Flinn et al. Blood 2018). Treatment‐emergent AEs (TEAEs) of special interest (AESIs) such as infections, diarrhea, colitis, neutropenia, rash, ALT/AST elevation, and pneumonitis, were moderate and manageable with early intervention and dose modification.Aims:To examine dose‐modification patterns and their impact on response to DUV in the DUO t..
View full abstract